Allakos Inc. (ALLK)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:44PM EDT. Market open.
| Previous close | 3.2100 |
| Open | 3.2800 |
| Bid | 3.3400 x 900 |
| Ask | 3.3500 x 800 |
| Day's range | 3.2100 - 3.4900 |
| 52-week range | 2.5400 - 112.8700 |
| Volume | |
| Avg. volume | 1,013,281 |
| Market cap | 185.099M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.5880 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.75 |
- GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis i
- Zacks
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
Allakos Inc. (ALLK) closed at $3.86 in the latest trading session, marking a -1.03% move from the prior day.
- Zacks
Allakos Inc. (ALLK) Gains As Market Dips: What You Should Know
In the latest trading session, Allakos Inc. (ALLK) closed at $5.46, marking a +0.18% move from the previous day.
© 2022 Yahoo. All rights reserved.
